IDEXX Laboratories Forecast, price target & analysts
IDEXX Laboratories Target price 2025 - Analyst rating & recommendation
IDEXX Laboratories Classifications & Recommendation:
IDEXX Laboratories Price Target
| Target Price | $514.10 |
| Price | $436.97 |
| Potential | 17.65% |
| Number of Estimates | 10 |
| 10 Analysts have issued a price target IDEXX Laboratories 2026 . The average IDEXX Laboratories target price is $514.10. This is 17.65% higher than the current stock price. The highest price target is $566.00 29.53% , the lowest is $420.00 3.88% . | |
| A rating was issued by 15 analysts: 8 Analysts recommend IDEXX Laboratories to buy, 7 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the IDEXX Laboratories stock has an average upside potential 2026 of 17.65% . Most analysts recommend the IDEXX Laboratories stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2028
11 Analysts have issued a sales forecast IDEXX Laboratories 2025 . The average IDEXX Laboratories sales estimate is $4.1b . This is 5.56% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $4.2b 6.81% , the lowest is $4.1b 4.70% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $3.9b | 6.46% |
|---|---|---|
| 2025 | $4.1b | 5.56% |
| 2026 | $4.4b | 7.83% |
| 2027 | $4.8b | 8.72% |
| 2028 | $5.2b | 8.45% |
8 Analysts have issued an IDEXX Laboratories EBITDA forecast 2025. The average IDEXX Laboratories EBITDA estimate is $1.4b . This is 14.06% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $1.6b 25.01% , the lowest is $1.4b 8.99% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $1.3b | 4.11% |
|---|---|---|
| 2025 | $1.4b | 14.09% |
| 2026 | $1.6b | 9.48% |
| 2027 | $1.7b | 8.17% |
| 2028 | $1.9b | 10.00% |
EBITDA Margin
| 2024 | 32.25% | 2.21% |
|---|---|---|
| 2025 | 34.86% | 8.08% |
| 2026 | 35.39% | 1.52% |
| 2027 | 35.21% | 0.51% |
| 2028 | 35.72% | 1.45% |
11 IDEXX Laboratories Analysts have issued a net profit forecast 2025. The average IDEXX Laboratories net profit estimate is $978m . This is 12.29% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $989m 13.59% , the lowest is $967m 11.06% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $871m | 6.06% |
|---|---|---|
| 2025 | $978m | 12.29% |
| 2026 | $1.1b | 12.71% |
| 2027 | $1.3b | 13.66% |
| 2028 | $1.4b | 13.71% |
Net Margin
| 2024 | 22.34% | 0.37% |
|---|---|---|
| 2025 | 23.76% | 6.36% |
| 2026 | 24.84% | 4.55% |
| 2027 | 25.97% | 4.55% |
| 2028 | 27.23% | 4.85% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
11 Analysts have issued a IDEXX Laboratories forecast for earnings per share. The average IDEXX Laboratories EPS is $11.98 . This is 12.28% higher than earnings per share in the financial year 2024. The highest EPS forecast is $12.12 13.59% , the lowest is $11.85 11.06% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $10.67 | 6.06% |
|---|---|---|
| 2025 | $11.98 | 12.28% |
| 2026 | $13.50 | 12.69% |
| 2027 | $15.35 | 13.70% |
| 2028 | $17.46 | 13.75% |
P/E ratio
| Current | 40.97 | 17.42% |
|---|---|---|
| 2025 | 36.47 | 10.98% |
| 2026 | 32.36 | 11.27% |
| 2027 | 28.47 | 12.02% |
| 2028 | 25.03 | 12.08% |
Based on analysts' sales estimates for 2025, the IDEXX Laboratories stock is valued at an EV/Sales of 8.78 and an P/S ratio of 8.61 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 9.26 | 19.48% |
|---|---|---|
| 2025 | 8.78 | 5.22% |
| 2026 | 8.14 | 7.26% |
| 2027 | 7.49 | 8.02% |
| 2028 | 6.90 | 7.79% |
P/S ratio
| Current | 9.09 | 19.82% |
|---|---|---|
| 2025 | 8.61 | 5.27% |
| 2026 | 7.98 | 7.26% |
| 2027 | 7.34 | 8.02% |
| 2028 | 6.77 | 7.79% |
IDEXX Laboratories...
Current IDEXX Laboratories Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Stifel |
Hold
➜
Hold
|
Unchanged | Apr 14 2025 |
| Piper Sandler |
Neutral
➜
Neutral
|
Unchanged | Feb 10 2025 |
| B of A Securities |
Neutral
➜
Neutral
|
Unchanged | Feb 04 2025 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Feb 04 2025 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Jan 29 2025 |
| Leerink Partners |
➜
Outperform
|
Initiated | Dec 02 2024 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Nov 04 2024 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Stifel:
Hold
➜
Hold
|
Apr 14 2025 |
|
Unchanged
Piper Sandler:
Neutral
➜
Neutral
|
Feb 10 2025 |
|
Unchanged
B of A Securities:
Neutral
➜
Neutral
|
Feb 04 2025 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Feb 04 2025 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Jan 29 2025 |
|
Initiated
Leerink Partners:
➜
Outperform
|
Dec 02 2024 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Nov 04 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
